Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inhibitors Of Virion Release01:25

Inhibitors Of Virion Release

Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...
Inhibitors of Virion Maturation and Assembly01:19

Inhibitors of Virion Maturation and Assembly

As part of their replication cycle, certain viruses synthesize long precursor proteins called polyproteins within infected host cells. In human immunodeficiency virus (HIV), two major polyproteins are produced: Gag and Gag-Pol. The Gag polyprotein supplies the structural components of the virus, while Gag-Pol includes essential viral enzymes such as reverse transcriptase, integrase, and protease. After synthesis, these polyproteins move to the host cell membrane, where they assemble into an...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a DNA...
Inhibitors of Bacterial DNA Synthesis01:28

Inhibitors of Bacterial DNA Synthesis

Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These antibiotics are selectively...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development and Qualification of a Nipah Virus Glycoprotein-Specific IgG ELISA for the Assessment of Human Antibody Responses.

Vaccines·2026
Same author

Potent in vitro antiviral activity of 4'-Fluorouridine against diverse orthohantaviruses including Andes virus.

Antiviral research·2026
Same author

Targeted cleavage site mutations in the Gn precursor enable efficient generation of replication-competent rVSV-based surrogates for emerging nairoviruses.

Emerging microbes & infections·2026
Same author

Recombinant Bombali ebolavirus in cynomolgus macaques as a survival model of Ebola virus disease.

Nature communications·2026
Same author

Distinct respiratory and neurological disease phenotypes in lethal Nipah virus Malaysia versus Bangladesh infection in IFNAR knockout mice.

Antiviral research·2026
Same author

Nucleoprotein and glycoprotein based serological assays for detection of Marburg virus infections.

EBioMedicine·2026
Same journal

Viral diversity in predatory insects used for biological control: Insights from a multi-country meta-viromic analysis.

Virology·2026
Same journal

Unveiling the hidden virome of Sclerotinia sclerotiorum: New tools and discoveries in mycovirus detection.

Virology·2026
Same journal

ASFV pDP238L negatively regulates type I interferon production via inhibiting the methylation of TBK1.

Virology·2026
Same journal

Divergent poxvirus identified in a non-native black rat from Madagascar.

Virology·2026
Same journal

Genomic and functional characterization of Bacillus phage BCE1 targeting a key gut bacterium in Aedes albopictus larvae.

Virology·2026
Same journal

Viral etiology of orogenital papillomatosis and squamous cell carcinoma in bottlenose dolphins in the southeastern United States.

Virology·2026
See all related articles

Related Experiment Video

Updated: Jun 21, 2026

Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes
10:11

Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes

Published on: September 27, 2014

RIG-I activation inhibits ebolavirus replication.

Christina F Spiropoulou1, Priya Ranjan, Melissa B Pearce

  • 1Special Pathogens Branch, Division of Viral and Rickettsial Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA. ccs8@cdc.gov

Virology
|July 25, 2009
PubMed
Summary
This summary is machine-generated.

RIG-I activation severely inhibits ebolavirus replication, offering a potential new antiviral strategy. This discovery could lead to therapies for Ebola hemorrhagic fever and other dangerous viral hemorrhagic fevers.

More Related Videos

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy
08:51

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy

Published on: April 3, 2018

Arbovirus Infections As Screening Tools for the Identification of Viral Immunomodulators and Host Antiviral Factors
06:02

Arbovirus Infections As Screening Tools for the Identification of Viral Immunomodulators and Host Antiviral Factors

Published on: September 13, 2018

Related Experiment Videos

Last Updated: Jun 21, 2026

Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes
10:11

Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes

Published on: September 27, 2014

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy
08:51

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy

Published on: April 3, 2018

Arbovirus Infections As Screening Tools for the Identification of Viral Immunomodulators and Host Antiviral Factors
06:02

Arbovirus Infections As Screening Tools for the Identification of Viral Immunomodulators and Host Antiviral Factors

Published on: September 13, 2018

Area of Science:

  • Virology
  • Immunology
  • Infectious Diseases

Background:

  • Hemorrhagic fever viruses (HFVs) cause severe, rapidly progressing disease with high fatality rates, posing significant public health and biothreat concerns.
  • Currently, effective broad-spectrum antivirals are lacking for most HFVs, necessitating novel therapeutic strategies.
  • Filoviruses, including ebolavirus and marburgvirus, are particularly challenging due to their high case fatality rates (80-90%) and aerosol infectivity.

Purpose of the Study:

  • To investigate the potential of activating host innate immune sensors as a broad-spectrum antiviral strategy against HFVs.
  • To determine if RIG-I activation can inhibit the replication of ebolavirus, a critical filovirus.

Main Methods:

  • Utilized molecular biology techniques to activate the RIG-I pathway in cells infected with ebolavirus.
  • Quantified the effect of RIG-I activation on viral replication levels.

Main Results:

  • Activation of RIG-I, an evolutionarily conserved cytosolic viral nucleic acid sensor, demonstrated significant inhibition of ebolavirus replication.
  • This finding highlights the potential of leveraging innate immune pathways for antiviral intervention.

Conclusions:

  • RIG-I activation presents a promising therapeutic avenue for combating Ebola hemorrhagic fever.
  • RIG-I-based therapies may offer a broad-spectrum approach against various hemorrhagic fever viruses.